ResistanceBio, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
ResistanceBio, Inc. - overview
Location
San Carlos, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded by Nick Goldner (CEO), and Chris Bulow (COO), ResistenceBio, a portfolio company of Alumni Ventures, is a biotechnology company that identifies and creates novel therapeutics for cancer patients who are resistant to clinical treatment. The firm employs its proprietary drug and target discovery platform, ResCu, that predicts the resistance of cancerous cells during clinical treatments to identify resistance target networks and resistance biomarkers that aid pharma companies in developing cancer treatments. The platform helps to determine the best drug for a cancer type, and the best patient population for treatment and identifies novel resistance targets for new therapies.
Current Investors
Alumni Ventures Group, Liquid 2 Ventures, NFX
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.resistance.bio
Verticals
HealthTech
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.